Corvus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Corvus Pharmaceuticals has a total shareholder equity of $12.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $58.8M and $46.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$41.65m |
| Equity | US$12.41m |
| Total liabilities | US$46.41m |
| Total assets | US$58.82m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: C17's short term assets ($42.9M) do not cover its short term liabilities ($46.4M).
Long Term Liabilities: C17 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: C17 is debt free.
Reducing Debt: C17 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: C17 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if C17 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.